A Research Guide for
Facing Glioblastoma

What to know, what to ask, and where to go — organized by where you are in the journey.

This guide is not medical advice. It is an educational research summary written in plain language, drawn from published medical literature and clinical trial records. Every important decision must be made together with the patient's medical team — neuro-oncologists, surgeons, and primary care doctors. Nothing here replaces those conversations. The purpose of this guide is to help patients and families walk into those conversations better prepared. This content does not create a doctor-patient relationship. OmniHealer's guides are written by medical researchers and patient advocates, not treating physicians. Laws regarding medical information vary by jurisdiction; consult a local licensed professional for advice specific to your situation.
Standard care first. Every option discussed in this guide is intended as an addition to, not a replacement for, the evidence-based standard treatments delivered by a qualified medical team. Treatments described as “alternative” to standard care, or claims that surgery, radiation, or chemotherapy can be safely skipped, are not supported by the medical evidence and are not endorsed by this guide.
Content last reviewed: May 2026  ·  Information changes frequently — always verify trial availability and treatment details with your medical team and primary sources.

Understanding Glioblastoma

The brain has two main types of cells: neurons (which handle thinking and signaling) and glial cells (support cells that feed, protect, and maintain the neurons). Glioblastoma is a cancer that starts in a type of glial cell called the astrocyte. It is classified as a grade 4 glioma — the most aggressive grade. Doctors often refer to it as GBM.

In the United States, approximately 12,000 new cases are diagnosed each year according to the Central Brain Tumor Registry of the United States (CBTRUS). Worldwide, the number is roughly 250,000 annually. This relatively small patient population has significant implications for treatment development and research funding.

What "average survival" actually means Published averages of 12 to 18 months include patients of all ages, health statuses, and treatment access levels. A younger patient in good general health, treated at a major cancer center with an active research program, may have a different outlook from that broad average, though individual outcomes vary widely and cannot be predicted. Population-based data report a five-year relative survival of approximately 6 to 8 percent; long-term survival beyond ten years occurs in fewer than 2 percent of patients. These are rare outcomes, not expectations.

Why Glioblastoma Is Especially Difficult

Three features of this disease drive treatment decisions and explain why progress has been slower than in many other cancers:

  • Invisible spread. By the time GBM appears on a scan, microscopic tumor cells have already extended into surrounding brain tissue. Even when a surgeon removes everything visible, some cells remain. This is why radiation and chemotherapy follow surgery in nearly every case.
  • The blood-brain barrier. A tightly sealed cellular layer lines the brain's blood vessels, blocking most drugs from reaching the tumor at useful concentrations. Many cancer drugs that work elsewhere in the body are ineffective against brain tumors because they cannot cross this barrier. Part 5 of this guide is devoted to this problem.
  • Intra-tumor diversity. Different parts of the same GBM can behave like different diseases. A drug that kills most cells may leave behind a resistant subpopulation that regrows. This is why treatment plans typically combine multiple approaches.

Molecular Markers: The Map That Personalizes Treatment

A piece of the tumor removed during surgery is sent to a laboratory for molecular testing. These results are among the most important pieces of information in the entire treatment plan. They predict how the tumor will respond to treatment and determine which clinical trials the patient may be eligible for.

Discuss all results with your medical team. The information below describes what each marker means in general. Your medical team can explain what each result means for your specific situation.

Key Markers to Request

  • MGMT promoter methylation — Predicts temozolomide response. Methylated tumors respond significantly better to chemotherapy and unlock an intensified regimen called CeTeG.
  • IDH1 and IDH2 mutation — If mutated, the diagnosis is technically a different disease (grade 4 astrocytoma) with a better prognosis and different treatment options.
  • BRAF V600E mutation — Rare in adult GBM, but if present opens a targeted drug combination with FDA approval across solid tumors.
  • NTRK fusion — Also rare, but opens specific targeted therapies with broad FDA approval.
  • MTAP deletion — Present in about 15% of GBMs; creates a vulnerability that experimental drugs in clinical trials can target.
  • H3 K27M mutation — Changes the WHO diagnosis to diffuse midline glioma. The FDA granted accelerated approval (2025) to dordaviprone (Modeyso) for patients aged 1 and older with H3 K27M-mutant diffuse midline glioma that has progressed after prior therapy. Continued approval depends on confirmatory trial results. Worth specifically requesting H3 K27M testing if not included in the standard panel.
  • Tumor mutational burden, microsatellite instability, mismatch repair status — Determine whether the tumor is "hypermutated," which may make immune checkpoint therapies more effective.
  • Surface markers (B7-H3, IL13Rα2, EGFRvIII, HER2) — Not always tested routinely but determine eligibility for several CAR-T cell therapy trials.
  • CMV (cytomegalovirus) status — Research suggests many GBMs show signs of CMV inside tumor cells, opening a conversation about antiviral add-on therapy.

The standard commercial panels for comprehensive testing include FoundationOne CDx, Tempus xT, and Caris Molecular Intelligence. If the treating center's in-house panel is more limited, a supplemental send-out can usually be arranged.

The molecular profile is worth more than any supplement decision. The branches in the molecular decision tree change survival meaningfully. Ensure this conversation with the oncologist happens early and thoroughly.

The First Weeks After Diagnosis

The period between surgery and the start of radiation/chemotherapy — typically two to six weeks — is the most time-sensitive window in GBM care. Several decisions made during this window can open or close options for the future.

What Matters Most Right Now

  • Ensure the standard care plan is well-organized and starting on time (radiation typically begins 2-6 weeks after surgery)
  • Get comprehensive molecular testing ordered and results reviewed
  • Start the second-opinion process at a major brain tumor center
  • Begin Optune (Tumor Treating Fields) insurance authorization — approval often takes weeks
  • Complete legal documents (will, advance directive, healthcare power of attorney) while cognition is fully intact
A note on urgency. The treatment clock is not as urgent as a heart attack, but more urgent than most cancers. This window defines how much time exists for second opinions, additional testing, and clinical trial screening.

Standard Treatment: The Foundation

Everything else in this guide builds on one principle: the treatments with the strongest evidence of extending life in GBM are the standard treatments. Experimental options, repurposed drugs, and clinical trials are considered in addition to standard care, never as replacements.

The standard sequence is:

  1. Surgery — Maximum safe removal of the tumor
  2. Chemoradiation — Six weeks of radiation combined with daily temozolomide (the Stupp protocol)
  3. Recovery period — Typically four weeks
  4. Maintenance chemotherapy — Several months of temozolomide (or CeTeG for MGMT-methylated tumors)
  5. Tumor Treating Fields (Optune) — Wearable device used alongside maintenance chemotherapy
Important safety note. If anyone suggests that standard care is harmful or unnecessary and that some alternative protocol can replace it, exercise extreme caution. Standard care is imperfect, but it has the strongest evidence of any approach by far. Build on it. Do not abandon it.

Surgery: Understanding What Was Done

The first treatment for nearly every newly diagnosed GBM is surgery. The goal is "maximal safe resection" — removing as much tumor as possible without damaging critical brain functions. Extent of resection is the single most important modifiable surgical factor.

Questions to Discuss with the Surgical Team

  • What was the extent of resection? Was a post-operative MRI performed within 24-72 hours?
  • Was 5-ALA fluorescence guidance (Gleolan) used? (This substance makes tumor cells glow under special surgical lighting)
  • Was extra fresh tumor tissue preserved for potential future personalized treatments? Was any tissue snap-frozen?
  • What molecular tests have been ordered on the tissue?
  • Is there enough tissue available to send to outside laboratories for expanded testing?

If tissue questions were not addressed at surgery, most items can still be investigated afterward — the original tissue block at the hospital pathology lab is typically usable for additional testing for months to years.

Chemoradiation: The Stupp Protocol

Named after Dr. Roger Stupp, whose landmark 2005 clinical trial established its value, this is a six-week course of radiation combined with daily temozolomide chemotherapy.

What to Expect

  • Radiation: 60 Gray delivered in 30 daily fractions over 6 weeks (Monday through Friday). Each session takes 15-30 minutes.
  • Temozolomide: A pill taken every day (including weekends) during radiation. It crosses the blood-brain barrier and damages DNA in dividing cancer cells.

Common Side Effects

  • Fatigue — Builds gradually, most pronounced in the final weeks and the month or two after.
  • Hair loss — In the radiation area; may be permanent in that specific area.
  • Nausea — Usually well controlled with ondansetron (Zofran) taken before each temozolomide dose.
  • Blood count changes — Regular monitoring is essential. The medical team will adjust doses if counts drop.

If MGMT Is Methylated: The CeTeG Discussion

For patients whose tumor is MGMT-methylated, an intensified regimen called CeTeG adds the chemotherapy drug lomustine to the standard protocol. In the published CeTeG/NOA-09 randomized trial (Herrlinger et al., Lancet 2019, 141 patients), MGMT-methylated patients on the lomustine-temozolomide combination had a median overall survival of approximately 48 months, versus approximately 31 months in patients on temozolomide alone. The trial population had selection criteria (age 18–70, Karnofsky ≥70) that may not match every individual patient. A subsequent real-world multicenter analysis reported median survival closer to 34 months. CeTeG has not yet changed standard-of-care guidelines and remains investigational; it may involve increased toxicity compared to standard temozolomide alone. Individual results vary substantially. Discuss with your neuro-oncologist whether the regimen, side-effect profile, and your specific clinical situation make this option appropriate.

Essential Supportive Care During Chemoradiation

  • PCP prophylaxis — Preventive antibiotics (typically trimethoprim-sulfamethoxazole) to prevent a serious lung infection. Standard of care during chemoradiation and should continue through maintenance temozolomide in patients who remain on steroids. Discuss duration with your medical team.
  • Anti-nausea medication — Ondansetron before each temozolomide dose.
  • Blood count monitoring — Weekly CBC during chemoradiation; before each maintenance cycle.
  • Blood clot awareness — GBM patients have a 20-30% rate of venous thromboembolism in the first year. Watch for one-sided leg swelling, sudden shortness of breath, or chest pain.
  • Acid reduction discussion — Recent research has suggested that certain proton pump inhibitors (omeprazole, pantoprazole) may be associated with less favorable outcomes. Discuss alternatives such as famotidine with your medical team.

Tumor Treating Fields (Optune)

Optune is a wearable device that delivers low-intensity alternating electrical fields through pads on the scalp. These fields interfere with how cancer cells divide without affecting normal brain function. A randomized trial showed meaningful improvement in overall survival when added to maintenance chemotherapy.

Wear time appears to matter. A post-hoc subgroup analysis of the pivotal trial (EF-14) reported that patients using the device for more than 90% of the time (about 22 hours/day) had longer median survival than those using it less than 75% of the time. Because this was a post-hoc analysis (not the primary endpoint), the finding is suggestive rather than definitive, and individual results vary. Maximizing comfortable, tolerable wear time — within the limits the medical team and the manufacturer's instructions recommend — is generally the practical goal.

Practical Considerations

  • Requires shaving the head every 3-5 days for pad adhesion
  • Skin care under the pads is important to prevent contact dermatitis (the most common reason patients reduce wear time)
  • The device weighs about three pounds with a battery carried in a shoulder bag
  • Most insurance plans cover Optune, but authorization takes time — start early
  • Novocure (the manufacturer) provides dedicated patient support for training, supplies, and insurance navigation

Steroid Management

Dexamethasone is commonly used to reduce brain swelling around the tumor. It is effective but carries significant side effects with prolonged use: muscle wasting, mood changes, increased infection risk, elevated blood sugar, insomnia, and weight gain. Long-term steroid use may also interfere with certain treatment strategies.

The practical goal is the lowest effective dose. Many patients can reduce their dose substantially over time, and some can taper off entirely. Discuss the taper plan with your medical team — do not adjust steroid doses independently, as sudden changes can cause serious problems.

Seizure Medications

Many GBM patients experience seizures at some point. Levetiracetam (Keppra) is the most common first choice due to its effectiveness and fewer drug interactions with chemotherapy. However, in approximately 10-20% of patients, it can cause mood changes, irritability, or anxiety. If this occurs, discuss alternatives such as brivaracetam or lacosamide with your medical team.

The Blood-Brain Barrier Problem

The blood-brain barrier (BBB) is the single biggest hidden obstacle in GBM treatment. Understanding it changes how to evaluate every drug claim and treatment recommendation.

Most cancer drugs developed in the last thirty years work well against tumors elsewhere in the body but cannot reach brain tumors at useful concentrations. The BBB tends to be partially broken down in the tumor bulk (which is why contrast dye shows up on MRI) but remains intact in surrounding tissue where the most dangerous infiltrating cells hide.

Three Strategies for Getting Around the BBB

A small number of cancer drugs cross the BBB on their own. Temozolomide is the prime example. Other drugs with reasonable BBB penetration include lomustine, mebendazole, and some newer targeted therapies. Many drugs that barely cross (pembrolizumab, carboplatin, most antibody-based drugs) need to be paired with a delivery strategy.

Low-intensity focused ultrasound with microbubbles: Tiny gas-filled microbubbles are infused intravenously. A focused ultrasound beam causes them to vibrate and gently push apart BBB cells for several hours, allowing drugs to flood in. Available as an implantable device (SonoCloud-9) or non-invasive transcranial systems.

Laser interstitial thermal therapy (LITT): Uses heat from a laser fiber to ablate tumor. As a side effect, opens the BBB in surrounding tissue for weeks afterward. This is why LITT combined with immunotherapy has shown some of the strongest recent results in recurrent GBM.

Convection-enhanced delivery (CED): Catheters placed surgically pump drugs directly into brain tissue.

Implanted brachytherapy (GammaTile): Biodegradable tiles loaded with radioactive seeds placed in the surgical cavity, delivering continuous local radiation.

The critical question for any treatment: How does this drug actually reach the tumor? If a treatment does not cross the BBB on its own, is not paired with a BBB-opening technology, and is not delivered directly into the brain, it is unlikely to work regardless of what laboratory data show.

Three Phases of Treatment

Phase 1: Immediate (Post-Surgery through Start of Chemoradiation)

Theme: Confirm what surgery achieved, establish molecular profile, prepare standard treatment backbone, add low-risk supportive layers. Typically lasts 2-6 weeks.

Phase 2: Short-Term (Months 1-3)

Theme: Layer additional strategies on top of standard chemoradiation. Match targeted therapies to molecular profile. Begin clinical trial conversations. Maintain Optune compliance above 90%.

Phase 3: Medium-Term (Months 3-9+)

Theme: Maintain treatment pressure. Monitor carefully. Write the recurrence playbook before recurrence happens. Pre-contact major centers and international options so logistics are not starting from zero if needed.

Pre-Chemoradiation Action Checklist

The items below cover work that ideally happens during the window between surgery and chemoradiation. Some can be done by family members on the patient's behalf.

  • Right Away
    Confirm comprehensive molecular testing has been ordered (MGMT, IDH, BRAF V600E, NTRK fusions, MTAP, H3 K27M, TMB, mismatch repair, surface markers)
  • Right Away
    Request CMV staining on the tumor tissue
  • Right Away
    Initiate Optune insurance authorization
  • Right Away
    Get post-operative MRI report, operative report, and tissue preservation details
  • Within First Week
    Arrange PCP prophylaxis for upcoming chemoradiation
  • Within First Week
    Ask about oncology dietitian referral; discuss glucose-ketone monitoring with medical team
  • Within First Week
    Submit second-opinion request to a major brain tumor center
  • 1-2 Weeks
    Discuss repurposed drug options with neuro-oncologist
  • 1-2 Weeks
    Discuss steroid taper plan
  • Within 2 Weeks
    Begin clinical trial screening
  • Within 2 Weeks
    Ask medical team about checking baseline vitamin D level (corticosteroid use can impact vitamin D levels)
  • 2-3 Weeks
    Complete will, advance directive, and powers of attorney
  • 2-3 Weeks
    Designate primary medical advocate; set up caregiver and transportation plan
  • Before Treatment
    Confirm anti-nausea plan and PCP prophylaxis are in place; baseline labs complete

Diet and Metabolic Strategy

GBM cells depend heavily on glucose for energy. Normal brain cells can switch to using ketones (produced when carbohydrates are restricted), but tumor cells are less flexible. The theoretical opportunity is to reduce glucose supply and create metabolic pressure on the tumor while normal cells function on ketones.

Evidence framing. Ketogenic therapy alongside standard care is mechanistically plausible, with encouraging early signals in some published studies. However, it has not yet been proven to extend survival in large randomized trials — notably, the ERGO2 randomized trial did not meet its primary endpoint of improved progression-free survival. The approach is best understood as a theoretical adjunct currently under active study (see the DIET2TREAT trial), not an established therapeutic intervention. Always discuss dietary changes with your medical team before implementing them.

Practical Implementation Points

  • Work with an oncology dietitian experienced with ketogenic protocols
  • Target less than 20-30 grams of net carbohydrate per day if pursuing strict keto
  • Monitor with a glucose-ketone meter daily
  • Protect body weight — Involuntary weight loss erases any metabolic advantage. If weight drops, adjust the approach.
  • A modified Atkins diet or time-restricted eating window is a reasonable alternative if strict keto is unsustainable

Exercise

Research suggests that maintaining physical activity during cancer treatment may help preserve muscle mass, support immune function, reduce fatigue, and lower blood sugar. Many oncology guidelines suggest aiming for approximately 30 minutes of activity on most days, but patients must consult their physical therapy or oncology team to establish safe, individualized exercise thresholds during treatment. Fall risk, deep vein thrombosis, and fatigue levels vary significantly between patients.

Sleep and Circadian Rhythm

Sleep quality may be supported by a dark, cool sleeping environment, consistent sleep timing, limiting caffeine, and morning daylight exposure. Some published studies have explored the use of melatonin as a sleep and circadian adjunct in oncology patients; patients interested in melatonin supplementation should discuss appropriate timing and dosages with their oncologist.

Dietary Supplement Notice: Statements regarding dietary supplements (including boswellia, melatonin, and curcumin) have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Always inform your medical team of any supplements you are taking or considering, as they may interact with prescribed treatments.

Candidates Worth Discussing with Your Medical Team

Off-Label Drug Information: The medications discussed in this section have not been approved by the U.S. Food and Drug Administration (FDA) for glioblastoma. They are approved for other conditions and have been studied in GBM to varying degrees. Using a drug off-label is a decision between the patient and their prescribing physician. This site does not endorse off-label use, recommend specific suppliers, or guarantee safety or efficacy. All evidence levels cited are from specific studies and do not predict individual outcomes. Discuss all options, risks, and potential interactions with your neuro-oncologist before considering any addition to standard care.

A small number of existing medications have enough published evidence to merit a conversation with the treating oncologist. None should be started without the oncologist's specific approval. All are considered additions to standard care, never replacements.

The principle of careful addition. Add one agent at a time, with 2-4 weeks of monitoring between additions and regular lab work, so that any problems can be attributed to the right cause. Adding multiple agents simultaneously makes troubleshooting impossible.

An anti-parasite drug with anti-cancer activity in laboratory studies. A Phase 1 trial at Johns Hopkins enrolled 24 patients with high-grade glioma alongside standard temozolomide. Published survival numbers were encouraging compared to historical expectations. The specific formulation matters — standard over-the-counter versions may not achieve adequate blood levels. Discuss sourcing and dosing with the oncologist. Main monitoring concern: liver enzymes.

A London-based clinic has published retrospective data on a combination of metformin, atorvastatin, mebendazole, and doxycycline used alongside standard care. Each component is a medication approved for other indications. The published evidence in glioblastoma is observational and limited — no large randomized controlled trial has been completed for this combination in GBM. Discuss individual components, potential interactions, and monitoring requirements with your oncologist.

A small randomized trial reported a reduction in MRI-measured peritumoral edema with a standardized boswellia preparation (high AKBA content) in irradiated brain tumor patients compared to placebo. Whether this translates to clinical benefit, reduced steroid need, or improved outcomes for any individual patient is unknown. Boswellia is a dietary supplement, not an FDA-approved drug. Discuss with your oncologist before adding it, particularly regarding potential interactions with other medications.

Research from the Karolinska Institute and others has reported that a high percentage of GBMs show signs of cytomegalovirus inside tumor cells. Published data suggest a possible survival association with the antiviral drug valganciclovir in CMV-positive patients, but the evidence has been debated in the field and the results have not been replicated in larger randomized trials. There is no FDA-approved use of valganciclovir for glioblastoma. The cost of testing the tumor for CMV is modest, and if positive it opens a conversation about whether adding an antiviral is appropriate. Discuss with your medical team.

  • St. John's Wort — Can significantly reduce blood levels of many drugs including chemotherapy. Avoid entirely during treatment.
  • Unregulated cannabis oil marketed as a cancer cure — Cannabis may be useful for symptom management (discuss with your team), but unregulated products marketed online as cancer cures are not standardized and lack evidence.
  • Intravenous vitamin C — No good evidence in GBM.
  • Stacking multiple herbal supplements simultaneously — Even individually safe supplements can become problematic when combined. Published case reports describe serious liver toxicity when multiple herbal supplements were taken alongside chemotherapy. Keep the list short and visible to your medical team.

Tissue Banking and Growing the Tumor Outside the Body

Several powerful future options depend on having the patient's tumor tissue preserved correctly. The key question is not whether everything ideal was done at surgery — but rather what is preserved and what remains possible with it.

What Banked Tissue Can Enable

  • Dendritic cell vaccines — Made from the patient's own immune cells, trained to recognize the specific tumor. Research continues on multiple fronts.
  • Organoid drug screening — Growing tumor cells in laboratory dishes to test which drugs work against this specific tumor. Available at a small number of academic centers.
  • Expanded molecular testing — Additional testing can often be performed on stored tissue months or years later.

If a second surgery ever becomes necessary, explicitly request snap-freezing of fresh tissue at that time.

The Molecular Decision Tree

Once molecular results return, the treatment plan branches. This is one of the most important decision points in the entire process.

Most Common Scenarios

These tumors respond significantly better to temozolomide. The most important decision is whether to use the CeTeG regimen (adding lomustine). Published trial data show a survival difference of roughly 16-17 additional months in the trial population. For an MGMT-methylated patient with good performance status, this is one of the most consequential conversations to have.

Standard temozolomide is less effective. Clinical trial enrollment becomes a higher priority. Key trials to ask about include Gliofocus (niraparib, a PARP inhibitor) and VAL-083 (a chemotherapy that bypasses MGMT resistance). Both have shown encouraging early data.

This technically changes the diagnosis to a different disease (astrocytoma, IDH-mutant, grade 4). The prognosis is generally better, and the treatment menu shifts. Vorasidenib (Voranigo) is FDA-approved for grade 2 IDH-mutant astrocytoma and oligodendroglioma only — not for grade 4. Trials in higher-grade IDH-mutant disease are ongoing. Eligibility for off-label use should be discussed with the medical team.

  • BRAF V600E: Opens dabrafenib + trametinib (FDA-approved across solid tumors)
  • NTRK fusion: Opens larotrectinib or entrectinib (tumor-agnostic FDA approval)
  • H3 K27M: Opens dordaviprone (Modeyso, FDA accelerated approval 2025 for recurrent/progressive disease after prior therapy)
  • MTAP deletion: Opens the MRTX1719 clinical trial
  • Hypermutated tumor: Makes immune checkpoint inhibitors more reasonable

Clinical Trials: A Treatment Option, Not a Last Resort

Trial Information Changes Frequently: Eligibility criteria, enrollment status, and available sites for clinical trials change on a weekly basis. The trials listed here were actively enrolling as of May 2026. Always verify current status on ClinicalTrials.gov or directly with the treating center before making plans. Participation in any trial is between the patient and the research team; this guide does not recommend or endorse specific trials.

Clinical trials should be considered alongside standard care, not only when other options fail. The Stupp protocol itself was once a trial. Every effective GBM treatment today started as a trial.

Key Trials to Ask About (2026)

  • Gliofocus (NCT06388733) — Phase 3 trial of niraparib vs. temozolomide in MGMT-unmethylated GBM. Study drug provided free. One of the highest-value trial considerations for unmethylated patients.
  • GBM AGILE (NCT03970447) — Platform trial testing multiple experimental treatments simultaneously. Available at many centers.
  • EF-41 / KEYNOTE D58 (NCT06556563) — Tests Optune + temozolomide + pembrolizumab. Entered after chemoradiation.
  • DIET2TREAT (NCT05708352) — Randomized trial of ketogenic diet plus standard care.
  • SONOBIRD (NCT04528680) — Phase 3 trial of SonoCloud-9 (BBB-opening) + carboplatin in recurrent GBM.

How to Search for Trials

Visit ClinicalTrials.gov, search for "glioblastoma," filter by "recruiting" status and location. Your cancer center's clinical trials office can also help identify eligible trials.

Patient Navigation Services

  • National Brain Tumor Society — Patient navigator: 800-934-2873
  • American Brain Tumor Association — CareLine: 800-886-2282
  • Musella Foundation — virtualtrials.org: 888-295-4740

If the Tumor Returns

Most GBM patients eventually experience recurrence. The treatments available at recurrence differ from initial treatment. Doing the thinking now — while the patient is still doing well — saves critical weeks when fast decisions matter.

Step 1: Confirm True Progression vs. Pseudoprogression

About 25% of patients show imaging changes after radiation that mimic tumor growth but are actually treatment-related inflammation. The medical team distinguishes these using perfusion MRI, amino-acid PET scanning, MR spectroscopy, or short-interval repeat imaging. Do not let an early suspicious scan trigger premature treatment changes.

Step 2: Repeat Molecular Testing

The tumor evolves under treatment pressure. If surgery is performed for recurrence, the new tissue should undergo full molecular profiling again — including surface markers for CAR-T eligibility.

Step 3: Salvage Pathway Options (Discuss with Medical Team)

  1. Repeat surgery with GammaTile — If the recurrence is focal and surgically accessible. GammaTile (Cs-131 brachytherapy) is available mainly at centers with neurosurgeons experienced in brachytherapy; not all centers offer it.
  2. LITT combined with immunotherapy — Early-phase studies have shown encouraging results for focal recurrence, but this combination remains investigational with limited data
  3. Re-irradiation — Feasible for many recurrences, especially with longer intervals from initial radiation
  4. BBB-opening drug delivery — Focused ultrasound trials at centers including Northwestern and University of Maryland
  5. Targeted molecular trials — Matched to the tumor's specific mutations
  6. CAR-T cell therapy — There is no approved CAR-T therapy for GBM; all options are early-phase clinical trials at major centers, requiring specific antigen expression on the tumor (B7-H3, IL13Rα2, EGFRvIII, or HER2)
  7. Oncolytic virus therapy — Including G47Δ (approved in Japan) and other investigational approaches
  8. Bevacizumab — Does not extend overall survival but can rapidly improve quality of life by controlling swelling
  9. International options — BNCT in Japan, NanoTherm in Germany (see International Options)

Decision Triggers — When to Act

  • New MRI shows possible recurrence: Request imaging copy and full radiology report. Ask the medical team within 48 hours for their interpretation.
  • Tumor confirmed as recurrent: Request expanded molecular testing. Contact pre-identified trial centers.
  • New seizures, weakness, speech changes, or confusion: Contact medical team within 24 hours.
  • Sudden shortness of breath or chest pain: Possible pulmonary embolism. Call 911.
  • Fever during chemotherapy: Neutropenic fever can be life-threatening. Contact the team same day.

Major Brain Tumor Centers by Region

No endorsement or affiliation. Listing here does not constitute a recommendation or endorsement of any specific center, physician, or program. OmniHealer has no financial relationship with any center listed. Specialties and trial participation noted are based on publicly available information as of May 2026 and may change. Verify all information directly with the center when contacting them.

The difference between a strong academic cancer center and a general community hospital can be significant for GBM. These centers have dedicated multidisciplinary brain tumor teams. Contact information is provided for new-patient inquiries — verify when calling, as details can change.

UCSF Brain Tumor Center

San Francisco, CA
Comprehensive neuro-oncology program, active trial portfolio
Neuro-Oncology: 415-353-2966 • Neurosurgery: 415-353-7500

Stanford Health Care

Stanford, CA
B7-H3 CAR-T cell therapy program
Phone: 650-498-6000

City of Hope

Duarte, CA
IL13Rα2 CAR-T cell therapy program
Brain Tumor Program: 626-218-6555

UCLA Brain Tumor Center

Los Angeles, CA
Dendritic cell vaccine research
Phone: 310-825-5111

Huntsman Cancer Institute

Salt Lake City, UT
NCI Comprehensive Cancer Center for the Mountain West. Proton therapy, GBM AGILE site, advanced surgical techniques.
Phone: 801-587-7000

Mayo Clinic — Phoenix

Phoenix, AZ
Active brain tumor program, clinical trials
Phone: 480-301-8000

Ivy Brain Tumor Center at Barrow Neurological Institute

Phoenix, AZ
Largest Phase 0 brain tumor trial program in the world. Sponsor of the Gliofocus trial.
Navigator: 602-406-8605 • Trial Screening: 602-406-6489

MD Anderson Cancer Center

Houston, TX
Major brain and spine center with extensive trial portfolio
New Patient: 877-632-6789 • Direct: 713-792-6600

Northwestern Memorial Hospital

Chicago, IL
Active SonoCloud-9 site for focused ultrasound BBB-opening trials
Lou & Jean Malnati Brain Tumor Institute: 312-695-4360

Washington University in St. Louis

St. Louis, MO
Major LITT center. Published landmark LITT + immunotherapy data.
Neurosurgery: 314-362-7172

Cleveland Clinic

Cleveland, OH
Rose Ella Burkhardt Brain Tumor Center. LITT and integrated brain tumor program.
Phone: 866-588-2264

Mayo Clinic — Rochester

Rochester, MN
Active brain tumor program across all three campuses
Phone: 507-538-3270

Henry Ford Hermelin Brain Tumor Center

Detroit, MI
Active brain tumor program with clinical trial participation
Phone: 888-777-4167

Duke Preston Robert Tisch Brain Tumor Center

Durham, NC
Pioneering immunotherapy and oncolytic virus research. Active LITT center.
Phone: 919-684-5301 • Screening: 866-385-3123

University of Florida Health

Gainesville, FL
LITT program, KEYNOTE D58 trial site
Phone: 352-265-1000

Mayo Clinic — Jacksonville

Jacksonville, FL
Active brain tumor program
Phone: 904-953-0853

Dana-Farber / Brigham Cancer Center

Boston, MA
Center for Neuro-Oncology. Major research and trial program.
Phone: 877-442-3324

Massachusetts General Hospital

Boston, MA
CAR-T cell therapy and immunotherapy research
Brain Tumor: 617-724-8770

Memorial Sloan Kettering Cancer Center

New York, NY
Comprehensive brain tumor center
New Patient: 800-525-2225

Weill Cornell Medicine

New York, NY
GBM organoid drug screening program
Brain & Spine: 212-746-4684

University of Pennsylvania

Philadelphia, PA
EGFRvIII CAR-T cell therapy program
Phone: 215-829-6700

University of Pittsburgh Medical Center

Pittsburgh, PA
Major LITT center
Phone: 412-647-3685

International Options

Several international centers offer treatments not yet approved in the United States. These are generally best held as recurrence contingencies — pre-planned while the patient is stable but executed when standard domestic options need escalation.

Important note on international treatments. G47Δ (Delytact), BNCT, and NanoTherm are not FDA-approved in the United States. They are regulated and approved under different frameworks in their home countries (Japan and the European Union). The standards used by foreign regulatory authorities differ from those of the FDA. Outcomes data from these centers come primarily from single-arm studies rather than randomized comparisons against U.S. standard of care. International medical travel during serious illness carries significant clinical, financial, and logistical risks. Discuss any international option with your U.S. medical team before committing, and obtain current written cost estimates and clinical eligibility confirmations directly from the international center.
Practical framing. International trips during the most aggressive disease window carry real costs in time, energy, and money. Pre-contact international centers early, hold them as contingencies, and use them when the timing fits. Avoid traveling overseas on hope alone when better-evidenced options remain available closer to home.

A triple-mutated herpes virus engineered to replicate inside cancer cells and stimulate an immune response. Conditionally approved in Japan since 2021 for malignant glioma — the first approved oncolytic virus for brain cancer anywhere in the world. Delivered by injection into residual or recurrent tumor at the University of Tokyo. Treatment requires a multi-week stay in Japan.

A precision radiation therapy where a boron-containing drug is taken up by tumor cells, then the area is irradiated with neutrons triggering a nuclear reaction that kills tumor cells with minimal damage to surrounding tissue. Available at centers in Osaka and Fukushima. Published data show encouraging survival numbers in recurrent glioma.

Magnetic iron oxide nanoparticles injected into the tumor generate heat when exposed to an external alternating magnetic field, directly damaging tumor cells. CE-marked in the European Union for recurrent GBM. Treatment at the MagForce center in Berlin.

Supporting the Patient and Family

Caregiver Support

  • Designate more than one caregiver — rotation prevents burnout
  • Set up help early using platforms like CaringBridge or Lotsa Helping Hands
  • Family Caregiver Alliance: 800-445-8106
  • Most cancer centers offer caregiver support groups

If Children Are Involved

Children need age-appropriate information. Trying to shield them entirely usually backfires. The American Cancer Society and CancerCare (800-813-4673) have resources specifically for helping families talk through these conversations.

Mental Health

  • Anxiety, depression, and existential distress are very common — they are part of what this disease does, not signs of weakness
  • Seek a therapist experienced with cancer or chronic illness
  • Medication options exist if mood symptoms develop
  • Mindfulness-based stress reduction and faith community support are both valuable

Legal and Practical Documents

Complete these in the first two to three weeks after diagnosis while cognition is fully intact:

  • Will (create or review)
  • Durable power of attorney for finances
  • Durable power of attorney for healthcare
  • Advance directive
  • Beneficiary designations on financial accounts
  • Digital asset access for a trusted person

Financial Resources

  • Patient Advocate Foundation: 800-532-5274
  • CancerCare: 800-813-4673 (financial assistance grants)
  • Musella Foundation: 888-295-4740 (brain tumor-specific assistance)
  • Social Security Disability (SSDI): GBM qualifies for Compassionate Allowance fast-track. Apply at 800-772-1213.
  • Optune (Novocure) patient services for insurance authorization: 1-855-281-9301

Travel Assistance for Treatment

  • Mercy Medical Angels: 757-318-9145
  • Air Charity Network: 877-621-7177
  • Corporate Angel Network: 914-328-1313
  • American Cancer Society Hope Lodge: 800-227-2345

An Honest Word on Hope

Honest hope is not the same as optimism. It holds two truths at once: that the average outcome is shorter than anyone wants, and that a real minority of patients live much longer than average. Honest hope does the practical work the situation requires — legal documents, financial planning, difficult conversations — while pursuing every reasonable treatment option.

Common Features of Long-Term Survivors

  • Younger age at diagnosis
  • Good general health before diagnosis
  • Complete or near-complete surgical resection
  • MGMT promoter methylation
  • Access to a strong cancer center with active trials
  • Engagement with research and willingness to consider experimental approaches
  • Strong family and social support
  • Consistent adherence to maintenance treatment

Several of these factors are changeable. The strength of the cancer center, engagement with research, treatment adherence, and family support are all things this guide can help with.

Palliative care is not hospice. Palliative care runs alongside active cancer treatment from the very beginning, focused on symptom management. Studies show early palliative care actually extends survival. Engage it early.

Top 7 Priorities for the Next Six to Nine Months

  1. Comprehensive molecular profiling — Full panel including the markers most people forget (H3 K27M, CMV, surface markers for CAR-T eligibility)
  2. Optune at maximum compliance — Target above 90% wear time. Discuss CeTeG if MGMT-methylated.
  3. The non-negotiable supportive layer — PCP prophylaxis, blood count monitoring, anti-nausea medication, PPI alternatives, blood clot awareness
  4. Discuss diet and metabolic approach with your team — Ask about ketogenic or modified Atkins protocols under oncology dietitian supervision. Discuss repurposed drug literature (including mebendazole) with your neuro-oncologist.
  5. Active trial enrollment — Screen for Gliofocus, GBM AGILE, EF-41/KEYNOTE D58, and others matched to molecular profile
  6. Pre-written recurrence playbook by month 3 — Identify LITT centers, confirm trial eligibility, pre-contact international centers
  7. The "free wins" — Steroid minimization, 30 minutes exercise 5-6 days/week, sleep protection, early palliative care

Questions to Ask Your Medical Team

  • What is the exact pathology diagnosis?
  • What molecular tests have been ordered? Will the panel include MGMT, IDH, BRAF V600E, NTRK, MTAP, H3 K27M, TMB, mismatch repair, surface markers?
  • Can the tumor tissue be stained for CMV?
  • What was the extent of resection on the post-operative MRI?
  • What is the proposed treatment plan? CeTeG if MGMT-methylated?
  • When will Optune start? Has authorization been initiated?
  • What clinical trials might this patient qualify for?
  • Is there any reason not to begin a ketogenic or modified Atkins diet?
  • What survival data are you quoting? Are those numbers from before or after Optune and CeTeG?
  • How will MRI monitoring be scheduled? Will perfusion imaging be included?
  • What is the second opinion strategy you would recommend?
  • Should we set up a baseline neuropsychological evaluation?
  • How do you handle urgent communication between appointments?
  • How will we tell true progression from pseudoprogression?
  • What salvage options are realistic at this center?
  • Is the patient a candidate for LITT + immunotherapy?
  • What CAR-T trials might apply based on tumor surface markers?
  • Should we consider ctDNA liquid biopsy monitoring?
  • What is the most realistic range of outcomes for this patient?
  • What can we do — beyond just receiving treatment — that actually makes a difference?
  • How do we know if and when to shift focus from active treatment to comfort-focused care?
  • Is there anything you wish more families would ask but usually don't?

Glossary

5-ALA (Gleolan)
Substance taken before surgery that makes GBM cells glow under blue light, helping surgeons identify tumor tissue.
BBB (Blood-Brain Barrier)
Tightly sealed cellular layer lining brain blood vessels. Keeps out most cancer drugs.
Bevacizumab (Avastin)
Drug that interferes with tumor blood vessel growth. Controls symptoms at recurrence but does not extend overall survival in trials.
CAR-T Cell Therapy
Patient's own T-cells engineered in a laboratory to recognize and attack specific proteins on cancer cells.
CeTeG
Intensified regimen adding lomustine to standard temozolomide for MGMT-methylated GBM. Published trial data show substantial survival benefit.
ctDNA
Circulating tumor DNA. Cancer cell DNA fragments found in blood or cerebrospinal fluid. Emerging monitoring tool.
GKI (Glucose-Ketone Index)
Blood glucose divided by blood ketones. Used to track ketosis depth. Target below 3, ideally below 2.
IDH Mutation
Changes the diagnosis to astrocytoma grade 4, a different disease with better prognosis and different treatment options.
LITT
Laser Interstitial Thermal Therapy. Laser-based tumor ablation that also opens the BBB in surrounding tissue.
MGMT Methylation
When the MGMT gene is silenced (methylated), temozolomide works significantly better. Key decision point for CeTeG.
Optune (TTFields)
Wearable device delivering electrical fields that disrupt cancer cell division. Dose-dependent on wear time.
Pseudoprogression
MRI changes mimicking tumor growth that are actually radiation-induced inflammation. Occurs in ~25% of patients.
Stupp Protocol
Standard treatment: surgery → 6 weeks radiation + temozolomide → maintenance temozolomide. Named for Dr. Roger Stupp.

Sources and Further Reading

This guide draws on published medical literature, clinical trial records, and the work of physicians who treat GBM. Key sources include landmark clinical trials, major cancer center protocols, and peer-reviewed research available through PubMed (pubmed.ncbi.nlm.nih.gov) and ClinicalTrials.gov.

Primary Resources

  • PubMed (pubmed.ncbi.nlm.nih.gov) — Free public database of medical research
  • ClinicalTrials.gov (clinicaltrials.gov) — Authoritative registry of clinical trials
  • NCCN Guidelines for Clinicians (nccn.org) — Treatment guidelines followed by virtually every oncologist
  • NCCN Guidelines for Patients (nccn.org/patientresources) — Free, patient-friendly versions of the clinical guidelines
  • National Cancer Institute (NCI) (cancer.gov/types/brain) — Comprehensive brain tumor information
  • FDA MedWatch (fda.gov/medwatch) — Report adverse events from any medication or supplement
  • Society for Neuro-Oncology (soc-neuro-onc.org) — Professional society for brain tumor specialists
  • Central Brain Tumor Registry of the US (CBTRUS) (cbtrus.org) — Population-based incidence and survival statistics
External links notice: Links to government agencies, academic institutions, and private organizations are provided for informational convenience. Linking does not constitute endorsement by OmniHealer, and we cannot attest to the accuracy of external content. You will be subject to the destination site's privacy policy when you leave this site.

Major Brain Tumor Organizations

A practical test for any online claim: If a website is making a claim about GBM treatment that does not appear anywhere in PubMed or NCCN guidelines, that should be a significant warning sign. The major medical bodies do not miss treatments that work.